Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements

Journal of Clinical Hypertension

Volumn 4, Issue 5, 2002, Pages 325-331

  Neutel, Joel M ^a   Elliott, William J ^a   Izzo, Joseph L ^a   Chen, Chao L ^a   Masonson, Harvey N ^a  

^a Orange County Heart Institute and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; OLMESARTAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PAIN; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SYSTOLIC BLOOD PRESSURE; VERTIGO;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0036750076     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2002.01051.x     Document Type: Article

References (15)

1. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637-645.
2. Yanagisawa H, Amemiya Y, Kanazaki T, et al. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxyliv acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-posotion and their related compounds. J Med Chem. 1996;39:323-338.
3. Anonymous. Olmesartan medoxomil. Drugs Future. 1997;22: 1205-1209.
4. Mizuno M, Sada T, Ikeda M, et al. Pharmacology of olmesartan medoxomil, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995;285:181-188.
5. Püchler K, Nussberger J, Laeis P, et al. Blood pressure and endocrine effects of single doses of olmesartan medoxomil, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens. 1997;15:1809-1812.
6. Diamant M, Idema RN, Vincent HH. The use of Fourier analysis in the calculation of trough to peak ratio from ambulatory blood pressure measurements. J Hum Hypertens. 1998;12:61-67.
7. Andrejak M, Genes N, Vaur L, et al. Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens. 2000;13:184-190.
8. White WB. Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit. 1997;2:47-51.
9. Staessen JA, Beilin L, Parati G, et al. Task force IV. clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. Blood Press Monit. 1999;4:319-331.
10. US Food and Drug Administration (FDA). Draft ICH principle: principles for clinical evaluation of new antihypertensive drugs. Available at www.fda.gov/cder/guidance/3774dft.pdf. Accessed January 23, 2001.
11. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
12. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf. 1999;21:23-33.
13. Hansson L, Smith DH, Reeves R, et al. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med. 2000;160:1654-1658.
14. 1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther. 1997;74:181-194.
15. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs. 1998;56:847-869.